Injectable Drug Delivery Articles

1. PLGA: A Workhorse Polymer Behind Modern Depot Long-Acting Injectables 8/7/2026

   PLGA-based long-acting injectables drive sustained drug delivery, with advances in generics, depot technologies, and manufacturing expanding patient access and innovation.

2. Designing Nanoparticles: Why Size Comes First 8/4/2026

   Successful nanoparticle programs choose size intentionally, taking into consideration the physical, chemical, and biological consequences of size.

3. From Vial To Prefilled Syringe: Mastering The Development Transition 8/3/2026

   In this article, Fran DeGrazio discusses the opportunities, challenges, and benefits for biopharmaceutical product developers in transitioning from vial-based to prefilled syringe (PFS) delivery approaches. She lays out key differences and added complexities in areas such as device functionality, risk management, regulatory pathways, use of materials, lifecycle management, and organizational alignment.

4. Rethinking The Blueprint For Bone Regeneration: The Next Evolution In Orthobiologics 7/22/2026

   Next-generation orthobiologics could transform spinal fusion by enabling targeted bone regeneration, improving safety, and reducing reliance on traditional grafts and hardware.

5. Can We Cure Diabetes? 7/15/2026

   We caught up with Minutia CEO Katy Digovich to discuss engineered iPSC-derived islets intended for transplantation into the forearm, which could make a functional cure for insulin-dependent diabetes broadly accessible.

6. Reassessing Nanoparticle Immunotoxicity: From Well-Established To Novel Approaches 7/14/2026

   This article highlights government-funded resources available to de-risk nanomedicines, reviews principles of immunotoxicity testing, and discusses emerging methodologies.

7. Delivery Device Functional Scrutiny: Can You Pass (Without) The Test? 7/13/2026

   In this article, Chief Editor Tom von Gunden considers the relationship between regulatory testing and the biopharma industry’s interest in leveraging drug delivery platform technologies to reduce regulatory burden in product development. Tom includes a conversation with guest columnist Doug Mead about waivers on testing in the context of FDA’s guidance on Essential Drug Delivery Outputs (EDDOs).  

8. Stability And Release Testing For Delivery Devices: Waived Or Wanted? 7/13/2026

   In this article, combination product consultant Doug Mead reports on precedent research he conducted on requests for FDA waivers on functional stability and release testing for drug delivery devices. He provides sample scenarios in the context of device design considerations for Essential Performance Requirements (EPRs) and the more recent FDA draft guidance on Essential Drug Delivery Outputs (EDDOs).

9. Enhancing Gene And Cell Therapies With Circular RNA-Based Gene Expression 6/29/2026

   While circular RNA platforms can enhance protein expression, developing effective delivery strategies remains the key challenge to achieving therapeutic efficacy.

10. Navigating Combination Products: Device Complexity And Software Integration 6/4/2026

    Software-enabled combination products demand early cross-functional alignment, regulatory foresight, and collaboration to avoid delays and accelerate patient access.